Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Radiation Therapy in Treating Patients With Cervical Cancer

Summary: RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
  PURPOSE: This phase II trial is studying how well giving external-beam radiation together with internal radiation works in treating patients with cervical cancer.

Detailed description: OBJECTIVES:
  Primary
  -  Determine the feasibility of magnetic resonance-guided, endocavitary, high-dose rate brachytherapy implants in patients with stage IB-IVB cervical cancer.
  -  Provide more reliable dose-volume estimations based on three-dimensional imaging-based treatment planning in patients treated with this regimen.
  Secondary
  -  Determine the toxic effects and treatment tolerance in patients treated with this regimen.
  -  Correlate three-dimensional dose-volume histograms of organs at risk with treatment toxicity in patients treated with this regimen.
  -  Determine the disease status, time and patterns of relapse, and survival of patients treated with this regimen.
  OUTLINE: Patients undergo external beam radiotherapy 4-5 days a week for up to 7 weeks. Patients also undergo MRI-guided high-dose brachytherapy comprising one brachytherapy implant a week for 3-6 implants. Brachytherapy may be administered during or after external beam radiotherapy.
  After completion of study treatment, patients are followed periodically for 5 years.
  PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.

Eligibility: DISEASE CHARACTERISTICS:
  -  Histologically confirmed carcinoma of the cervix of 1 of the following cellular subtypes:
  -  Squamous cell
  -  Adenocarcinoma
  -  Adenosquamous cell
  -  Stages IB-IVA disease
  -  Stage IVB disease allowed provided the impact on the quality of life is tremendous (e.g., "frozen pelvis" or massive pelvic disease and fistula formation, severe pain, or bleeding)
  -  Measurable and/or evaluable disease on MRI
  PATIENT CHARACTERISTICS:
  -  ECOG performance status 0-2
  -  No physical or physiological capacity that would preclude study treatment
  -  No cognitively impaired patients who cannot provide informed consent
  -  Not pregnant or nursing
  -  Negative pregnancy test
  -  No contraindication to MRI, including any of the following:
  -  Weight > 136 kg
  -  Allergy to MR contrast agent
  -  Pacemakers, cerebral aneurysm clips, shrapnel injury, or implantable electronic devices
  -  No significant unrelated systemic illness
  -  No serious infections
  -  No significant cardiac, pulmonary, hepatic, or other organ dysfunction that would preclude study treatment
  -  Must be medically fit to receive anesthesia
  PRIOR CONCURRENT THERAPY:
  -  No prior definitive brachytherapy procedures
  -  Ring implants or intravaginal cones for the relief of excessive bleeding allowed
  -  No prior definitive surgical oncologic procedures (e.g., radical hysterectomy)
  -  Concurrent chemotherapy, immunotherapy, or hormonal therapy allowed

Relevance to patient case: not relevant